CoChat

Increased Genetic Risk for β-Cell Failure Is Associated With β-Cell Function Decline in People With Prediabetes

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 19 of the 19 sources its claims cite were checked for support.

Abstract

Partitioned polygenic scores (pPS) have been developed to capture pathophysiologic processes underlying type 2 diabetes (T2D). We investigated the association of T2D pPS with diabetes-related traits and T2D incidence in the Diabetes Prevention Program. We generated five T2D pPS (β-cell, proinsulin, liver/lipid, obesity, lipodystrophy) in 2,647 participants randomized to intensive lifestyle, metformin, or placebo arms. Associations were tested with general linear models and Cox regression with adjustment for age, sex, and principal components. Sensitivity analyses included adjustment for BMI. Higher β-cell pPS was associated with lower insulinogenic index and corrected insulin response at 1-year follow-up with adjustment for baseline measures (effect per pPS SD -0.04, P = 9.6 × 10-7, and -8.45 μU/mg, P = 5.6 × 10-6, respectively) and with increased diabetes incidence with adjustment for BMI at nominal significance (hazard ratio 1.10 per SD, P = 0.035). The liver/lipid pPS was associated with reduced 1-year baseline-adjusted triglyceride levels (effect per SD -4.37, P = 0.001). There was no significant interaction between T2D pPS and randomized groups. The remaining pPS were associated with baseline measures only. We conclude that despite interventions for diabetes prevention, participants with a high genetic burden of the β-cell cluster pPS had worsening in measures of β-cell function.

Overview

CoChat Summary

TL;DR

In the Diabetes Prevention Program, higher partitioned polygenic score (pPS) for β-cell failure was associated with worse baseline and 1-year β-cell function despite lifestyle or metformin intervention. The findings suggest diabetes prevention interventions may not optimally preserve β-cell function in people with genetic susceptibility to β-cell dysfunction.

Key findings

  • Among 2,647 DPP participants, higher β-cell pPS was associated with lower 1-year baseline-adjusted corrected insulin response (CIR; effect per SD −0.042 [95% CI −0.058, −0.025], P = 9.6 × 10−7) and insulinogenic index (IGR; −8.498 μU/mg [−12.166, −4.830], P = 5.6 × 10−6).
  • Higher β-cell pPS was also associated with increased diabetes incidence in the BMI-adjusted model at nominal significance (hazard ratio 1.10 per SD [95% CI 1.00, 1.20], P = 0.035), not meeting the study-wide significance threshold.
  • Higher liver/lipid pPS was associated with reduced 1-year baseline-adjusted triglyceride levels (effect per SD −4.37 [−6.98, −1.76], P = 1.0 × 10−3).
  • No significant interaction was found between any T2D pPS and randomized treatment group; the remaining pPS were associated with baseline measures only.

Methods

  • Secondary analysis of the U.S. multicenter randomized DPP trial, including 2,647 participants with genotyping and baseline and 1-year measurements who were randomized to intensive lifestyle, metformin, or placebo.
  • Five T2D pPS (β-cell, proinsulin, obesity, lipodystrophy, liver/lipid) were generated from previously identified T2D genetic clusters.
  • Generalized linear models tested associations with baseline and 1-year traits adjusted for baseline values, age, sex, and top 10 principal components; Cox proportional hazards models tested diabetes incidence. Sensitivity analyses adjusted for BMI and restricted to self-reported White race; Bonferroni α = 0.001 was used for 10 novel outcomes.

Limitations

  • The paper states limited sample size from an existing clinical study impacted power, and the DPP population’s narrow weight range may have reduced ability to replicate some baseline associations.
  • The paper states the genetic clusters were developed in studies of predominantly European genetic ancestry, with additional efforts underway for more diverse ancestral groups.
  • The paper states that although significant associations were identified, effect sizes were small, suggesting cluster pPS stratification would not be clinically useful at this point.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/db23-0761

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Figure 1 Greater decline in insulin secretory response over 1 year in the highest quartile of b -cell cluster pPS. In participants in the highest quartile of b -cell cluster pPS compared with those in the lowest quartile, the adjusted means of measures of b -cell secretory response estimated with IGR ( A ) and CIR ( B ) both signi fi cantly decline from baseline to 1 year ( P < 0.001). IGR ( m U/mg) = (insulin30 min  insulin 0 min ) / (glucose30 min  glucose0 min). CIR = (100 × insulin30 min) / [glucose30-min × (glucose30-min  70 mg/dL)].
Figure 1 Greater decline in insulin secretory response over 1 year in the highest quartile of b -cell cluster pPS. In participants in the highest quartile of b -cell cluster pPS compared with those in the lowest quartile, the adjusted means of measures of b -cell secretory response estimated with IGR ( A ) and CIR ( B ) both signi fi cantly decline from baseline to 1 year ( P < 0.001). IGR ( m U/mg) = (insulin30 min insulin 0 min ) / (glucose30 min glucose0 min). CIR = (100 × insulin30 min) / [glucose30-min × (glucose30-min 70 mg/dL)].From the PDF

Verification

Claims the paper makes

5 Valid · 3 Not valid · 0 Not checked · 58 Own results and interpretations

35 more claims · 1 with their cited sources checked

Create a free account to see all 66 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 11
  • Not yet classified. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 36 references

Cited by

See all 11

Metadata

Authors
Billings, L. K., Jablonski, K. A., Pan, Q., Florez, J. C., Franks, P. W., Goldberg, R. B., Hivert, M.-F., Kahn, S. E., Knowler, W. C., Lee, C. G., Merino, J., Huerta-Chagoya, A., Mercader, J. M., Raghavan, S., Shi, Z., Srinivasan, S., Xu, J., & Udler, M. S.
Affiliations
  • Endeavor Health (US)
  • George Washington University (US)
  • 8Diabetes Unit, Massachusetts General Hospital, Boston, MA
  • Harvard University (US)
  • University of Miami (US)
  • University of Washington (US)
  • National Institutes of Health (US)
  • Broad Institute (US)
  • 12Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA
  • VA Eastern Colorado Health Care System (US)
  • University of California, San Francisco (US)
Corresponding author
  • Billings, Liana K.
  • Udler, Miriam S.
Venue
Diabetes
Published
2024-05-17
Volume
73
Issue
8
Pages
1352-1360
ISSN
0012-1797 (ISSN-L)
OpenAlex
W4397002598
Cited by
11
References
30
Citations by year
2026: 5 · 2025: 6
FWCI
2.91
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion)
  • PubMed Central (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • American Diabetes Association (7-21-JDFM-005)
  • Nutrition Obesity Research Center at Harvard (P30 DK040561)
  • National Institutes of Health (UG1 HD107691)
  • US Department of Veterans Affairs (IK2-CX001907)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114551, U01 DK048339, U01 DK048349, U01 DK048375, U01 DK048377, U01 DK048380, U01 DK048381, U01 DK048387, U01 DK048397, U01 DK048400, U01 DK048404, U01 DK048406, U01 DK048407, U01 DK048411, U01 DK048412, U01 DK048413, U01 DK048434, U01 DK048437, U01 DK048443, U01 DK048468, U01 DK048485, U01 DK048489, U01 DK048514)
  • Boettcher Foundation (Webb Waring Biomedical Research Award)
  • NIH (UG1 HD107691)
  • NorthShore University HealthSystem (NorthShore Auxiliary Scholars Award)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
type 2 diabetes, beta-cell function, prediabetes, insulinogenic index, type 2 diabetes incidence, Diabetes Prevention Program, metformin, lifestyle intervention, triglycerides, genetic risk, beta-cell failure
MeSH terms
Adult, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Prediabetic State, Incidence, Genetic Predisposition to Disease, Multifactorial Inheritance, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.